SynthesisBreast (Edinburgh, Scotland)2024

The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials.

Merve Keskinkilic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.